Aline Navega Biz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aline Navega Biz has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Rosângela Caetano
Universidade do Estado do Rio de Janeiro (UERJ), Brasil
4 shared publications Rondineli Mendes da Silva
Núcleo de Assistência Farmacêutica, Escola Nacional de Saúde Pública Sérgio Arouca, Fiocruz
3 shared publications- Ione Ayala Gualandi de Oliveira
Universidade do Estado do Rio de Janeiro (UERJ), Brasil
2 shared publications - Paul Tappenden
Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK
2 shared publications - Ricardo Ewbank Steffen
Universidade do Estado do Rio de Janeiro, Brazil
2 shared publications - Abdullah Pandor
Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- p. 1-164
PillCam COLON 2 for investigation of the colon through direct visualisation: systematic review and economic evaluation
Background: Colorectal cancer is the fourth most common cancer and the second most common cause of cancer deaths in England. Most cases of colorectal cancer arise from a prior adenomatous polyp in the bowel lining. Colonoscopy is the gold standard investigation for people with symptoms suggestive of colorectal cancer. During a colonoscopy, polyps can be removed or a biopsy can be taken. However, waiting times for colonoscopy can be long and the procedure can be unpleasant. Colon capsule endoscopy may provide an alternative diagnostic procedure to rule out polyps or colorectal cancer. Objectives: To evaluate the clinical effectiveness, acceptability and cost-effectiveness of colon capsule endoscopy using PillCam COLON 2 for detecting colorectal polyps and colorectal cancer. Methods and data sources: A systematic review searched six bibliographic databases and eight conference proceedings in August 2024. Studies of PillCam COLON 2 in symptomatic or polyp surveillance patients were included if they were randomised controlled trials, or if they reported data on diagnostic test accuracy, yield or patient preference. Bayesian pooling of sensitivity and specificity was performed. The economic analysis included a review of existing models and development of an independent model to assess the cost-effectiveness of colon capsule endoscopy versus colonoscopy and computed tomography colonography in three main populations (symptomatic patients with a faecal immunochemical test score of 10–100 μg/g, symptomatic faecal immunochemical test < 10 μg/g and surveillance patients). Subgroup analyses were conducted in patients who are able and willing to undergo colonoscopy and those who are not (denoted ‘COL-eligible’ and ‘COL-ineligible’). Results: Among the diagnostic test accuracy studies (11–64% patients ‘in-scope’), for polyps of any size (two studies), ≥ 6 mm (four studies) and ≥ 10 mm (four studies), pooled sensitivities were 0.78 (95% credible interval 0.51 to 0.90), 0.83 (95% credible interval 0.70 to 0.91) and 0.85 (95% credible interval 0.70 to 0.94), respectively. Specificities were 0.60 (95% credible interval 0.27 to 0.88), 0.69 (95% credible interval 0.52 to 0.81) and 0.90 (95% credible interval 0.82 to 0.95), respectively. Among yield studies, colonoscopy was spared in 37–50% of symptomatic patients (three studies). Data on colonoscopy spared in surveillance patients were available from one study; however, these data are confidential and cannot be reported here. In patients unwilling/unable to undergo colonoscopy, colon capsule endoscopy completed 70–98% of incomplete colonoscopies. Patient preference studies indicated general satisfaction with PillCam COLON 2, but some conflicting information on patient preference for colon capsule endoscopy compared to colonoscopy and computed tomography colonography. For colonoscopy-eligible patients, within all three main analysis populations, the External Assessment Group’s model suggests that colon capsule endoscopy is expected to lead to small quality-adjusted life-year losses and higher costs than colonoscopy; hence, colon capsule endoscopy is dominated by colonoscopy. For colonoscopy-ineligible patients, colon capsule endoscopy either dominated by computed tomography colonography or has an incremental cost-effectiveness ratio which is markedly higher than £30,000 per quality-adjusted life-year gained. Despite these findings, colon capsule endoscopy is predicted to lead to substantial reductions in the number of colonoscopies required, particularly for symptomatic patients who are able to undergo colonoscopy. Limitations: The generalisability of the diagnostic test accuracy data to symptomatic and polyp surveillance patients was unclear. Conclusions: Colon capsule endoscopy is expected to be less effective and more expensive than colonoscopy. However, it could help to free up constrained colonoscopy services, particularly in people with symptoms suggestive of bowel cancer. Study registration: The systematic review protocol is available on the PROSPERO website (registration number CRD42024586405). Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR136010) and is published in full in Health Technology Assessment ; Vol. 30, No. 58. See the NIHR Funding and Awards website for further award information.
- 1 July 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- p. 1-164
Open AccessPillCam COLON 2 for investigation of the colon through direct visualisation: systematic review and economic evaluation
Background: Colorectal cancer is the fourth most common cancer and the second most common cause of cancer deaths in England. Most cases of colorectal cancer arise from a prior adenomatous polyp in the bowel lining. Colonoscopy is the gold standard investigation for people with symptoms suggestive of colorectal cancer. During a colonoscopy, polyps can be removed or a biopsy can be taken. However, waiting times for colonoscopy can be long and the procedure can be unpleasant. Colon capsule endoscopy may provide an alternative diagnostic procedure to rule out polyps or colorectal cancer. Objectives: To evaluate the clinical effectiveness, acceptability and cost-effectiveness of colon capsule endoscopy using PillCam COLON 2 for detecting colorectal polyps and colorectal cancer. Methods and data sources: A systematic review searched six bibliographic databases and eight conference proceedings in August 2024. Studies of PillCam COLON 2 in symptomatic or polyp surveillance patients were included if they were randomised controlled trials, or if they reported data on diagnostic test accuracy, yield or patient preference. Bayesian pooling of sensitivity and specificity was performed. The economic analysis included a review of existing models and development of an independent model to assess the cost-effectiveness of colon capsule endoscopy versus colonoscopy and computed tomography colonography in three main populations (symptomatic patients with a faecal immunochemical test score of 10–100 μg/g, symptomatic faecal immunochemical test < 10 μg/g and surveillance patients). Subgroup analyses were conducted in patients who are able and willing to undergo colonoscopy and those who are not (denoted ‘COL-eligible’ and ‘COL-ineligible’). Results: Among the diagnostic test accuracy studies (11–64% patients ‘in-scope’), for polyps of any size (two studies), ≥ 6 mm (four studies) and ≥ 10 mm (four studies), pooled sensitivities were 0.78 (95% credible interval 0.51 to 0.90), 0.83 (95% credible interval 0.70 to 0.91) and 0.85 (95% credible interval 0.70 to 0.94), respectively. Specificities were 0.60 (95% credible interval 0.27 to 0.88), 0.69 (95% credible interval 0.52 to 0.81) and 0.90 (95% credible interval 0.82 to 0.95), respectively. Among yield studies, colonoscopy was spared in 37–50% of symptomatic patients (three studies). Data on colonoscopy spared in surveillance patients were available from one study; however, these data are confidential and cannot be reported here. In patients unwilling/unable to undergo colonoscopy, colon capsule endoscopy completed 70–98% of incomplete colonoscopies. Patient preference studies indicated general satisfaction with PillCam COLON 2, but some conflicting information on patient preference for colon capsule endoscopy compared to colonoscopy and computed tomography colonography. For colonoscopy-eligible patients, within all three main analysis populations, the External Assessment Group’s model suggests that colon capsule endoscopy is expected to lead to small quality-adjusted life-year losses and higher costs than colonoscopy; hence, colon capsule endoscopy is dominated by colonoscopy. For colonoscopy-ineligible patients, colon capsule endoscopy either dominated by computed tomography colonography or has an incremental cost-effectiveness ratio which is markedly higher than £30,000 per quality-adjusted life-year gained. Despite these findings, colon capsule endoscopy is predicted to lead to substantial reductions in the number of colonoscopies required, particularly for symptomatic patients who are able to undergo colonoscopy. Limitations: The generalisability of the diagnostic test accuracy data to symptomatic and polyp surveillance patients was unclear. Conclusions: Colon capsule endoscopy is expected to be less effective and more expensive than colonoscopy. However, it could help to free up constrained colonoscopy services, particularly in people with symptoms suggestive of bowel cancer. Study registration: The systematic review protocol is available on the PROSPERO website (registration number CRD42024586405). Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR136010) and is published in full in Health Technology Assessment ; Vol. 30, No. 58. See the NIHR Funding and Awards website for further award information.
- Open Access
- 12 August 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (11)
Cost-utility analysis of memantine in Alzheimer’s Disease in Brazil
Accelerated population aging has led to a progressive increase in dementia, particularly Alzheimer’s Disease (AD). The study’s objective was to perform a cost-utility analysis on the use of memantine in the severe stage of AD in Brazil compared to no specific pharmacological treatment from the perspective of the Brazilian Unified Health System (SUS). A Markov model was designed to simulate the progression of AD through five finite stages of health that considered cognitive function and a time horizon of five years. Progression probabilities were derived from clinical trials and population-based studies. Direct costs included hospitalization, medical consultation, use of additional medications, as well as laboratory tests. The measures for Quality Adjusted Life Year (QALY) were derived from the international literature. Costs and benefits were discounted by 5%. Compared to no specific pharmacological treatment, memantine was associated with gains in QALY and additional costs. The model showed that memantine resulted in a gain of 0.00308 QALY over the simulated 5 years and an increase in costs of R$351.50 per patient in already discounted values, resulting in an incremental cost-effectiveness ratio (ICER) of R$114,123.38 per QALY. The cost and effect of memantine on AD progression were the variables under the most uncertainty. Although memantine represents gains in QALY, its ICER is considered high for the Brazilian context considering its high costs and its small and limited benefit in time.
- 12 August 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (11)
Open AccessCost-utility analysis of memantine in Alzheimer’s Disease in Brazil
Accelerated population aging has led to a progressive increase in dementia, particularly Alzheimer’s Disease (AD). The study’s objective was to perform a cost-utility analysis on the use of memantine in the severe stage of AD in Brazil compared to no specific pharmacological treatment from the perspective of the Brazilian Unified Health System (SUS). A Markov model was designed to simulate the progression of AD through five finite stages of health that considered cognitive function and a time horizon of five years. Progression probabilities were derived from clinical trials and population-based studies. Direct costs included hospitalization, medical consultation, use of additional medications, as well as laboratory tests. The measures for Quality Adjusted Life Year (QALY) were derived from the international literature. Costs and benefits were discounted by 5%. Compared to no specific pharmacological treatment, memantine was associated with gains in QALY and additional costs. The model showed that memantine resulted in a gain of 0.00308 QALY over the simulated 5 years and an increase in costs of R$351.50 per patient in already discounted values, resulting in an incremental cost-effectiveness ratio (ICER) of R$114,123.38 per QALY. The cost and effect of memantine on AD progression were the variables under the most uncertainty. Although memantine represents gains in QALY, its ICER is considered high for the Brazilian context considering its high costs and its small and limited benefit in time.
- Open Access
- 3 May 2022
- Published by Revista Brasileira de Farmacia Hospitalar e Servicos de Saude in Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
- Vol. 13 (2) , 804
The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access
The United Kingdom has universal healthcare systems, the National Health System (NHS), in its four nations, with healthcare services provided free of charge at the point of delivery. Approximately 10.5% of the UK population has voluntary supplementary private health insurance. While the provision of inpatient medicines is free of charge, medicines provided in the outpatient setting have a dispensing fee in some of the nations, such as the case of England (co-payment). The UK marketing authorisation process is called product licensing and is overseen by the Medicines and Healthcare Products Regulatory Agency (MHRA). There are different licensing routes based on the intended market for launch. MHRA also offers early access schemes and pathways for products targeting unmet medical needs and promising technologies, that aim to accelerate and facilitate market and patient access to products in the UK. These schemes include the option for companies to engage early with regulators and other system partners such as health technology assessment (HTA) agencies. As soon as the technology is authorised, it is available at a list price. Prices for medicines are regulated in legislation and in schemes agreed between the industry association and the Department of Health and Social Care (DHSC). The prices for the NHS are negotiated between the government and the companies. Routine funding decisions in the NHS are guided by HTA evaluations informed by agencies such as the National Institute for Health and Care Excellence (NICE) in England, the Scottish Medicines Consortium (SMC) in Scotland, and the All Wales Medicines Strategy Group (AWMSG) in Wales. Many medicines and other technologies are subject to price negotiations in the NHS, sometimes with confidential price agreements. The NHS in England is legally mandated to routinely fund technologies recommended by NICE that have been evaluated by some of its programmes. The other UK nations have similar arrangements or recognise decisions made in England. The role and contribution of NICE and other HTA agencies in ensuring value for money and evidence-based decision making is well recognised worldwide.
- 3 May 2022
- Published by Revista Brasileira de Farmacia Hospitalar e Servicos de Saude in Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
- Vol. 13 (2) , 804
Open AccessThe regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access
The United Kingdom has universal healthcare systems, the National Health System (NHS), in its four nations, with healthcare services provided free of charge at the point of delivery. Approximately 10.5% of the UK population has voluntary supplementary private health insurance. While the provision of inpatient medicines is free of charge, medicines provided in the outpatient setting have a dispensing fee in some of the nations, such as the case of England (co-payment). The UK marketing authorisation process is called product licensing and is overseen by the Medicines and Healthcare Products Regulatory Agency (MHRA). There are different licensing routes based on the intended market for launch. MHRA also offers early access schemes and pathways for products targeting unmet medical needs and promising technologies, that aim to accelerate and facilitate market and patient access to products in the UK. These schemes include the option for companies to engage early with regulators and other system partners such as health technology assessment (HTA) agencies. As soon as the technology is authorised, it is available at a list price. Prices for medicines are regulated in legislation and in schemes agreed between the industry association and the Department of Health and Social Care (DHSC). The prices for the NHS are negotiated between the government and the companies. Routine funding decisions in the NHS are guided by HTA evaluations informed by agencies such as the National Institute for Health and Care Excellence (NICE) in England, the Scottish Medicines Consortium (SMC) in Scotland, and the All Wales Medicines Strategy Group (AWMSG) in Wales. Many medicines and other technologies are subject to price negotiations in the NHS, sometimes with confidential price agreements. The NHS in England is legally mandated to routinely fund technologies recommended by NICE that have been evaluated by some of its programmes. The other UK nations have similar arrangements or recognise decisions made in England. The role and contribution of NICE and other HTA agencies in ensuring value for money and evidence-based decision making is well recognised worldwide.
- 1 October 2021
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- Vol. 9 (11) , 1-146
An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT
Background: People with cystic fibrosis frequently have low levels of adherence to inhaled medications. Objectives: The objectives were to develop and evaluate an intervention for adults with cystic fibrosis to improve adherence to their inhaled medication. Design: We used agile software methods to develop an online platform. We used mixed methods to develop a behaviour change intervention for delivery by an interventionist. These were integrated to become the CFHealthHub intervention. We undertook a feasibility study consisting of a pilot randomised controlled trial and process evaluation in two cystic fibrosis centres. We evaluated the intervention using an open-label, parallel-group randomised controlled trial with usual care as the control. Participants were randomised in a 1 : 1 ratio to intervention or usual care. Usual care consisted of clinic visits every 3 months. We undertook a process evaluation alongside the randomised controlled trial, including a fidelity study, a qualitative interview study and a mediation analysis. We undertook a health economic analysis using both a within-trial and model-based analysis. Setting: The randomised controlled trial took place in 19 UK cystic fibrosis centres. Participants: Participants were people aged ≥ 16 years with cystic fibrosis, on the cystic fibrosis registry, not post lung transplant or on the active transplant list, who were able to consent and not using dry-powder inhalers. Intervention: People with cystic fibrosis used a nebuliser with electronic monitoring capabilities. This transferred data automatically to a digital platform. People with cystic fibrosis and clinicians could monitor adherence using these data, including through a mobile application (app). CFHealthHub displayed graphs of adherence data as well as educational and problem-solving information. A trained interventionist helped people with cystic fibrosis to address their adherence. Main outcome measures: Randomised controlled trial – adjusted incidence rate ratio of pulmonary exacerbations meeting the modified Fuchs criteria over a 12-month follow-up period (primary outcome); change in percentage adherence; and per cent predicted forced expiratory volume in 1 second (key secondary outcomes). Process evaluation – percentage fidelity to intervention delivery, and participant and interventionist perceptions of the intervention. Economic modelling – incremental cost per quality-adjusted life-year gained. Results: Randomised controlled trial – 608 participants were randomised to the intervention (n = 305) or usual care (n = 303). To our knowledge, this was the largest randomised controlled trial in cystic fibrosis undertaken in the UK. The adjusted rate of exacerbations per year (primary outcome) was 1.63 in the intervention and 1.77 in the usual-care arm (incidence rate ratio 0.96, 95% confidence interval 0.83 to 1.12; p = 0.638) after adjustment for covariates. The adjusted difference in mean weekly normative adherence was 9.5% (95% confidence interval 8.6% to 10.4%) across 1 year, favouring the intervention. Adjusted mean difference in forced expiratory volume in 1 second (per cent) predicted at 12 months was 1.4% (95% confidence interval –0.2% to 3.0%). No adverse events were related to the intervention. Process evaluation – fidelity of intervention delivery was high, the intervention was acceptable to people with cystic fibrosis, participants engaged with the intervention [287/305 (94%) attended the first intervention visit], expected mechanisms of action were identified and contextual factors varied between randomised controlled trial sites. Qualitative interviews with 22 people with cystic fibrosis and 26 interventionists identified that people with cystic fibrosis welcomed the objective adherence data as proof of actions to self and others, and valued the relationship that they built with the interventionists. Economic modelling – the within-trial analysis suggests that the intervention generated 0.01 additional quality-adjusted life-years at an additional cost of £865.91 per patient, leading to an incremental cost-effectiveness ratio of £71,136 per quality-adjusted life-year gained. This should be interpreted with caution owing to the short time horizon. The health economic model suggests that the intervention is expected to generate 0.17 additional quality-adjusted life-years and cost savings of £1790 over a lifetime (70-year) horizon; hence, the intervention is expected to dominate usual care. Assuming a willingness-to-pay threshold of £20,000 per quality-adjusted life-year gained, the probability that the intervention generates more net benefit than usual care is 0.89. The model results are dependent on assumptions regarding the duration over which costs and effects of the intervention apply, the impact of the intervention on forced expiratory volume in 1 second (per cent) predicted and the relationship between increased adherence and drug-prescribing levels. Limitations: Number of exacerbations is a sensitive and valid measure of clinical change used in many trials. However, data collection of this outcome in this context was challenging and could have been subject to bias. It was not possible to measure baseline adherence accurately. It was not possible to quantify the impact of the intervention on the number of packs of medicines prescribed. Conclusions: We developed a feasible and acceptable intervention that was delivered to fidelity in the randomised controlled trial. We observed no statistically significant difference in the primary outcome of exacerbation rates over 12 months. We observed an increase in normative adherence levels in a disease where adherence levels are low. The magnitude of the increase in adherence may not have been large enough to affect exacerbations. Future work: Given the non-significant difference in the primary outcome, further research is required to explore why an increase in objective normative adherence did not reduce exacerbations and to develop interventions that reduce exacerbations. Trial registration: Work package 3.1: Current Controlled Trials ISRCTN13076797. Work packages 3.2 and 3.3: Current Controlled Trials ISRCTN55504164. Funding: This project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research; Vol. 9, No. 11. See the NIHR Journals Library website for further project information.
- 1 October 2021
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- Vol. 9 (11) , 1-146
An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT
Background: People with cystic fibrosis frequently have low levels of adherence to inhaled medications. Objectives: The objectives were to develop and evaluate an intervention for adults with cystic fibrosis to improve adherence to their inhaled medication. Design: We used agile software methods to develop an online platform. We used mixed methods to develop a behaviour change intervention for delivery by an interventionist. These were integrated to become the CFHealthHub intervention. We undertook a feasibility study consisting of a pilot randomised controlled trial and process evaluation in two cystic fibrosis centres. We evaluated the intervention using an open-label, parallel-group randomised controlled trial with usual care as the control. Participants were randomised in a 1 : 1 ratio to intervention or usual care. Usual care consisted of clinic visits every 3 months. We undertook a process evaluation alongside the randomised controlled trial, including a fidelity study, a qualitative interview study and a mediation analysis. We undertook a health economic analysis using both a within-trial and model-based analysis. Setting: The randomised controlled trial took place in 19 UK cystic fibrosis centres. Participants: Participants were people aged ≥ 16 years with cystic fibrosis, on the cystic fibrosis registry, not post lung transplant or on the active transplant list, who were able to consent and not using dry-powder inhalers. Intervention: People with cystic fibrosis used a nebuliser with electronic monitoring capabilities. This transferred data automatically to a digital platform. People with cystic fibrosis and clinicians could monitor adherence using these data, including through a mobile application (app). CFHealthHub displayed graphs of adherence data as well as educational and problem-solving information. A trained interventionist helped people with cystic fibrosis to address their adherence. Main outcome measures: Randomised controlled trial – adjusted incidence rate ratio of pulmonary exacerbations meeting the modified Fuchs criteria over a 12-month follow-up period (primary outcome); change in percentage adherence; and per cent predicted forced expiratory volume in 1 second (key secondary outcomes). Process evaluation – percentage fidelity to intervention delivery, and participant and interventionist perceptions of the intervention. Economic modelling – incremental cost per quality-adjusted life-year gained. Results: Randomised controlled trial – 608 participants were randomised to the intervention (n = 305) or usual care (n = 303). To our knowledge, this was the largest randomised controlled trial in cystic fibrosis undertaken in the UK. The adjusted rate of exacerbations per year (primary outcome) was 1.63 in the intervention and 1.77 in the usual-care arm (incidence rate ratio 0.96, 95% confidence interval 0.83 to 1.12; p = 0.638) after adjustment for covariates. The adjusted difference in mean weekly normative adherence was 9.5% (95% confidence interval 8.6% to 10.4%) across 1 year, favouring the intervention. Adjusted mean difference in forced expiratory volume in 1 second (per cent) predicted at 12 months was 1.4% (95% confidence interval –0.2% to 3.0%). No adverse events were related to the intervention. Process evaluation – fidelity of intervention delivery was high, the intervention was acceptable to people with cystic fibrosis, participants engaged with the intervention [287/305 (94%) attended the first intervention visit], expected mechanisms of action were identified and contextual factors varied between randomised controlled trial sites. Qualitative interviews with 22 people with cystic fibrosis and 26 interventionists identified that people with cystic fibrosis welcomed the objective adherence data as proof of actions to self and others, and valued the relationship that they built with the interventionists. Economic modelling – the within-trial analysis suggests that the intervention generated 0.01 additional quality-adjusted life-years at an additional cost of £865.91 per patient, leading to an incremental cost-effectiveness ratio of £71,136 per quality-adjusted life-year gained. This should be interpreted with caution owing to the short time horizon. The health economic model suggests that the intervention is expected to generate 0.17 additional quality-adjusted life-years and cost savings of £1790 over a lifetime (70-year) horizon; hence, the intervention is expected to dominate usual care. Assuming a willingness-to-pay threshold of £20,000 per quality-adjusted life-year gained, the probability that the intervention generates more net benefit than usual care is 0.89. The model results are dependent on assumptions regarding the duration over which costs and effects of the intervention apply, the impact of the intervention on forced expiratory volume in 1 second (per cent) predicted and the relationship between increased adherence and drug-prescribing levels. Limitations: Number of exacerbations is a sensitive and valid measure of clinical change used in many trials. However, data collection of this outcome in this context was challenging and could have been subject to bias. It was not possible to measure baseline adherence accurately. It was not possible to quantify the impact of the intervention on the number of packs of medicines prescribed. Conclusions: We developed a feasible and acceptable intervention that was delivered to fidelity in the randomised controlled trial. We observed no statistically significant difference in the primary outcome of exacerbation rates over 12 months. We observed an increase in normative adherence levels in a disease where adherence levels are low. The magnitude of the increase in adherence may not have been large enough to affect exacerbations. Future work: Given the non-significant difference in the primary outcome, further research is required to explore why an increase in objective normative adherence did not reduce exacerbations and to develop interventions that reduce exacerbations. Trial registration: Work package 3.1: Current Controlled Trials ISRCTN13076797. Work packages 3.2 and 3.3: Current Controlled Trials ISRCTN55504164. Funding: This project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research; Vol. 9, No. 11. See the NIHR Journals Library website for further project information.
- 1 October 2019
- Published by Elsevier in Value in Health Regional Issues
- Vol. 19, S22
PCN51 SYSTEMATIC REVIEW AND META-ANALYSIS OF 18F-FDG PET-CT FOR INITIAL STAGING OF PATIENTS WITH ESOPHAGEAL CANCER
- 1 October 2019
- Published by Elsevier in Value in Health Regional Issues
- Vol. 19, S22
PCN51 SYSTEMATIC REVIEW AND META-ANALYSIS OF 18F-FDG PET-CT FOR INITIAL STAGING OF PATIENTS WITH ESOPHAGEAL CANCER
- Open Access
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Geriatria e Gerontologia
- Vol. 22 (4)
A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
Objective: To synthesize the available evidence and state of the art of economic evaluations which evaluate the use of memantine, whether alone or combined with donepezil, for moderate to severe Alzheimer’s disease (AD), focusing on the analytical decision models built. Method: The electronic databases MEDLINE, EMBASE, NHS EED, CEA Registry and LILACS were searched for references. After duplicates were removed, two independent reviewers evaluated the titles and abstracts and subsequently the full texts. The Drummond M. tool was used to evaluate the quality of the studies. Results: After the application of the eligibility criteria, twelve complete economic evaluations were included. One evaluation was a clinical trial, two involved simulations and nine used Markov models. The main outcome measure adopted was dominated by cost per quality adjusted life year (QALY). The use of memantine was considered cost-effective and dominant in eight studies; while in a single study, its use was dominated when compared to donepezil for moderate AD. Sensitivity analyzes were systematically performed, with robust results. The quality assessment indicated that the methodological quality of the studies was good. Conclusion: Although there is some controversy regarding the benefits derived from the use of memantine, whether combined or not with donepezil, the evidence collected suggests that it is cost-effective in the countries where the studies were performed. However, local economic studies need to be performed, given the significant variability derived from the different parameters adopted in the evaluations.
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Geriatria e Gerontologia
- Vol. 22 (4)
Open AccessA systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease
Objective: To synthesize the available evidence and state of the art of economic evaluations which evaluate the use of memantine, whether alone or combined with donepezil, for moderate to severe Alzheimer’s disease (AD), focusing on the analytical decision models built. Method: The electronic databases MEDLINE, EMBASE, NHS EED, CEA Registry and LILACS were searched for references. After duplicates were removed, two independent reviewers evaluated the titles and abstracts and subsequently the full texts. The Drummond M. tool was used to evaluate the quality of the studies. Results: After the application of the eligibility criteria, twelve complete economic evaluations were included. One evaluation was a clinical trial, two involved simulations and nine used Markov models. The main outcome measure adopted was dominated by cost per quality adjusted life year (QALY). The use of memantine was considered cost-effective and dominant in eight studies; while in a single study, its use was dominated when compared to donepezil for moderate AD. Sensitivity analyzes were systematically performed, with robust results. The quality assessment indicated that the methodological quality of the studies was good. Conclusion: Although there is some controversy regarding the benefits derived from the use of memantine, whether combined or not with donepezil, the evidence collected suggests that it is cost-effective in the countries where the studies were performed. However, local economic studies need to be performed, given the significant variability derived from the different parameters adopted in the evaluations.
- Open Access
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Cadernos de Saude Publica
- Vol. 35 (8) , e00129118
Carga do tabagismo no Brasil e benefício potencial do aumento de impostos sobre os cigarros para a economia e para a redução de mortes e adoecimento
A prevalência do tabagismo no Brasil reduziu sobremaneira nas últimas décadas, mas o país ainda tem uma elevada carga de doença associada a este fator de risco. O objetivo deste trabalho foi estimar a carga de mortalidade, morbidade e custos para a sociedade associada ao tabagismo em 2015 e o potencial impacto gerado em desfechos de saúde e para a economia a partir do aumento de preços dos cigarros por meio de impostos. Foram desenvolvidos dois modelos: o primeiro é um modelo matemático baseado em uma microssimulação probabilística de milhares de indivíduos usando-se coortes hipotéticas que considerou a história natural, custos e a qualidade de vida destes indivíduos. O segundo é um modelo de impostos aplicado para estimar o benefício econômico e em desfechos de saúde de diferentes cenários de aumento de preços em 10 anos. O tabagismo foi responsável por 156.337 mortes, 4,2 milhões de anos de vida perdidos, 229.071 infartos agudos do miocárdio, 59.509 acidentes vasculares cerebrais e 77.500 diagnósticos de câncer. O custo total foi de R$ 56,9 bilhões, dos quais 70% corresponderam ao custo direto associado à assistência à saúde e o restante ao custo indireto devido à perda de produtividade por morte prematura e incapacidade. Um aumento de 50% do preço do cigarro evitaria 136.482 mortes, 507.451 casos de doenças cardiovasculares, 64.382 de casos de câncer e 100.365 acidentes vasculares cerebrais. O benefício econômico estimado seria de R$ 97,9 bilhões. Concluiu-se que a carga da doença e econômica associada ao tabagismo é elevada no Brasil e o aumento de impostos é capaz de evitar mortes, adoecimento e custos para a sociedade.
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Cadernos de Saude Publica
- Vol. 35 (8) , e00129118
Open AccessCarga do tabagismo no Brasil e benefício potencial do aumento de impostos sobre os cigarros para a economia e para a redução de mortes e adoecimento
A prevalência do tabagismo no Brasil reduziu sobremaneira nas últimas décadas, mas o país ainda tem uma elevada carga de doença associada a este fator de risco. O objetivo deste trabalho foi estimar a carga de mortalidade, morbidade e custos para a sociedade associada ao tabagismo em 2015 e o potencial impacto gerado em desfechos de saúde e para a economia a partir do aumento de preços dos cigarros por meio de impostos. Foram desenvolvidos dois modelos: o primeiro é um modelo matemático baseado em uma microssimulação probabilística de milhares de indivíduos usando-se coortes hipotéticas que considerou a história natural, custos e a qualidade de vida destes indivíduos. O segundo é um modelo de impostos aplicado para estimar o benefício econômico e em desfechos de saúde de diferentes cenários de aumento de preços em 10 anos. O tabagismo foi responsável por 156.337 mortes, 4,2 milhões de anos de vida perdidos, 229.071 infartos agudos do miocárdio, 59.509 acidentes vasculares cerebrais e 77.500 diagnósticos de câncer. O custo total foi de R$ 56,9 bilhões, dos quais 70% corresponderam ao custo direto associado à assistência à saúde e o restante ao custo indireto devido à perda de produtividade por morte prematura e incapacidade. Um aumento de 50% do preço do cigarro evitaria 136.482 mortes, 507.451 casos de doenças cardiovasculares, 64.382 de casos de câncer e 100.365 acidentes vasculares cerebrais. O benefício econômico estimado seria de R$ 97,9 bilhões. Concluiu-se que a carga da doença e econômica associada ao tabagismo é elevada no Brasil e o aumento de impostos é capaz de evitar mortes, adoecimento e custos para a sociedade.
- 1 October 2018
- Published by Elsevier in Value in Health
- Vol. 21, S246
PMD22 - THE EFFECTIVENESS OF ELECTRONIC LARYNX FOR SPEECH REHABILITATION OF LARINGECTOMIZED PATIENTS: A REVIEW OF THE LITERATURE
- 1 October 2018
- Published by Elsevier in Value in Health
- Vol. 21, S246
PMD22 - THE EFFECTIVENESS OF ELECTRONIC LARYNX FOR SPEECH REHABILITATION OF LARINGECTOMIZED PATIENTS: A REVIEW OF THE LITERATURE
- Open Access
- 1 August 2017
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 22 (8) , 2513-2525
Incorporação de novos medicamentos pela Comissão Nacional de Incorporação de Tecnologias do SUS, 2012 a junho de 2016
Resumo A Comissão Nacional de Incorporação de Tecnologias em Saúde (Conitec), instituída em 2011, assessora o Ministério da Saúde nas decisões relacionadas à incorporação, exclusão ou alteração de novos medicamentos, produtos e procedimentos no Sistema Único de Saúde. O estudo investigou o processo de recomendação pela Conitec e o perfil das demandas e incorporações de medicamentos, de janeiro/2012 a junho/2016. A fonte de dados baseou-se nos registros disponíveis no site da Conitec. Demandas foram classificadas pelos tipos de submissão, de tecnologia e demandante. Medicamentos incorporados foram analisados segundo as classificações Anatômico-Terapêutica-Química e Internacional de Doença (CID) da indicação clínica, e presença de registro na Agência Nacional de Vigilância Sanitária. Foram recebidas 485 submissões, 92,2% relativas a pedidos de incorporação e 62,1% para medicamentos, dos quais 93 (30,1%) com recomendação favorável à incorporação. Demandas internas obtiveram maior sucesso que as originadas externamente. Seis medicamentos sem registro foram incorporados. Doenças infecto-parasitárias e osteomusculares foram as principais indicações clínicas. Benefícios clínicos adicionais e baixo impacto orçamentário foram as principais justificativas de recomendação.
- 1 August 2017
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 22 (8) , 2513-2525
Open AccessIncorporação de novos medicamentos pela Comissão Nacional de Incorporação de Tecnologias do SUS, 2012 a junho de 2016
Resumo A Comissão Nacional de Incorporação de Tecnologias em Saúde (Conitec), instituída em 2011, assessora o Ministério da Saúde nas decisões relacionadas à incorporação, exclusão ou alteração de novos medicamentos, produtos e procedimentos no Sistema Único de Saúde. O estudo investigou o processo de recomendação pela Conitec e o perfil das demandas e incorporações de medicamentos, de janeiro/2012 a junho/2016. A fonte de dados baseou-se nos registros disponíveis no site da Conitec. Demandas foram classificadas pelos tipos de submissão, de tecnologia e demandante. Medicamentos incorporados foram analisados segundo as classificações Anatômico-Terapêutica-Química e Internacional de Doença (CID) da indicação clínica, e presença de registro na Agência Nacional de Vigilância Sanitária. Foram recebidas 485 submissões, 92,2% relativas a pedidos de incorporação e 62,1% para medicamentos, dos quais 93 (30,1%) com recomendação favorável à incorporação. Demandas internas obtiveram maior sucesso que as originadas externamente. Seis medicamentos sem registro foram incorporados. Doenças infecto-parasitárias e osteomusculares foram as principais indicações clínicas. Benefícios clínicos adicionais e baixo impacto orçamentário foram as principais justificativas de recomendação.
- Open Access
- 1 March 2016
- Published by FapUNIFESP (SciELO) in Physis: Revista de Saúde Coletiva
- Vol. 26 (1) , 331-356
Custo-efetividade do uso da tomografia de emissão de pósitrons na detecção de recorrência do câncer diferenciado de tireoide
Avaliou-se a custo-efetividade da adição da tomografia de emissão de pósitrons (18FDG-PET-TC) aos métodos convencionais na detecção de recorrência de cânceres diferenciados de tireoide. O modelo analítico de decisão representou coorte hipotética de pacientes adultos, de alto risco pela estratificação inicial, submetidos a tireoidectomia total e ablação com I131. A estratégia convencional de detecção foi comparada à adição da 18FDG-PET-TC aplicada aos indivíduos com resultados de cintigrafia com I131 negativos. O horizonte temporal foi de dez anos. Utilizou-se a perspectiva do Sistema Único de Saúde (SUS) e, como medida de efetividade, os casos adicionais diagnosticados pela inclusão da PET-TC. Foram considerados apenas os custos médicos diretos. O custo do PET-TC foi estimado por microcustos; os demais custos foram obtidos das tabelas de pagamento de procedimentos do SUS. Custos e benefícios foram descontados em 5%. Realizaram-se análises de sensibilidade determinística univariada e probabilística. Detectaram-se 1.875 casos de recorrência com a estratégia convencional. Uso da 18FDG-PET-TC permitiu a detecção adicional de 13 casos, com custo de R$477.633,05/caso detectado. Os parâmetros de maior impacto na análise foram: medidas de acurácia dos métodos convencionais, custo do PET-TC e taxa de desconto. Os custos da adição da PET-TC mostram-se significativos e sua introdução não é custo-efetiva.
- 1 March 2016
- Published by FapUNIFESP (SciELO) in Physis: Revista de Saúde Coletiva
- Vol. 26 (1) , 331-356
Open AccessCusto-efetividade do uso da tomografia de emissão de pósitrons na detecção de recorrência do câncer diferenciado de tireoide
Avaliou-se a custo-efetividade da adição da tomografia de emissão de pósitrons (18FDG-PET-TC) aos métodos convencionais na detecção de recorrência de cânceres diferenciados de tireoide. O modelo analítico de decisão representou coorte hipotética de pacientes adultos, de alto risco pela estratificação inicial, submetidos a tireoidectomia total e ablação com I131. A estratégia convencional de detecção foi comparada à adição da 18FDG-PET-TC aplicada aos indivíduos com resultados de cintigrafia com I131 negativos. O horizonte temporal foi de dez anos. Utilizou-se a perspectiva do Sistema Único de Saúde (SUS) e, como medida de efetividade, os casos adicionais diagnosticados pela inclusão da PET-TC. Foram considerados apenas os custos médicos diretos. O custo do PET-TC foi estimado por microcustos; os demais custos foram obtidos das tabelas de pagamento de procedimentos do SUS. Custos e benefícios foram descontados em 5%. Realizaram-se análises de sensibilidade determinística univariada e probabilística. Detectaram-se 1.875 casos de recorrência com a estratégia convencional. Uso da 18FDG-PET-TC permitiu a detecção adicional de 13 casos, com custo de R$477.633,05/caso detectado. Os parâmetros de maior impacto na análise foram: medidas de acurácia dos métodos convencionais, custo do PET-TC e taxa de desconto. Os custos da adição da PET-TC mostram-se significativos e sua introdução não é custo-efetiva.